Pfizer Inc.: Stable Dividend Giant Positioned for Long-Term Biopharma Growth
Company Overview
- Ticker: PFE(NYSE)
- Headquarters: New York
- Founded: 1849
- CEO: Albert Bourla
- Industry: Drug Manufacturers – General
Core Business
The company discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
- Primary Product: The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis and the Premarin family brands infectious diseases with unmet medical needs under the Prevnar family and Trumenba brands and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Additional Services: It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz and Cibinqo brands amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta and Talzenna brands.
- Customer Base: Company serves to healthcare providers such as doctors, hospitals, clinics and pharmacies.
- Distribution: Company uses a multi-channel distribution strategy combining direct shipments from its manufacturing facilities to medical sites with indirect distribution via authorized wholesalers and distributors.
Industry Overview
- Valuation: The industry experiences steady growth driven by aging populations, rising chronic diseases, biotech innovation, and expanding healthcare access worldwide.
- Trends: There is a growing focus on novel drug modalities such as antibody-drug conjugates, oligonucleotides, and gene therapies targeting high unmet medical needs.
- Competition: Abbvie Inc, AMGEN Inc, GSK Plc ADR, Lilly (Eli) & Co, Sanofi ADR, Johnson & Johnson, Merck & Co Inc.
- Growth Drivers: Market demand for specialty drugs, personalized medicines, and novel therapies continues to drive capacity expansion.
Key Growth Drivers
- High Profitability: Company’s current high profitability is driven by strong revenue performance and effective cost management. The company expects full-year revenues between $61 to $64 billion, with EPS of $3.00 to $3.15, reflecting operational growth of 10% to 18% year.
- Market Share Expansion: PFE maintains leadership in key therapeutic areas with blockbuster products like Eliquis, Prevnar, and Vyndaqel contributing significantly to its revenue.
- Financial Strength: PFE maintains a stable credit rating of ‘A’ from S&P Global, indicating a strong ability to meet financial obligations.
- Undervaluation: The company’s price-to-earnings ratio currently stands around 14-15, which is below its historical average.
Dividend Profile
- Dividend Yield: 6.37%
- Payout Ratio: 120.11%
- Dividend Growth: 16 consecutive years of dividend increase.
- Sustainability: Well-covered dividend supported by free cash flow. Paying dividends for the last 40 years.
Financial Overview (FY 2024)
- Revenue: $63.62 billion
- Net Income: $8.02 billion
- Operating Income: $14.83 billion
- Total Assets: $213.39 billion
- Total Debt: $63.64 billion
- P/E Ratio (Current): 14.8
Key Financials
Risks
Target
Right now, the company is trading at US $24.88, with a 1-year projected target of around US $28 and a low estimation of US $24.50; the average price target will be US $27.25.
MarketFacts gives a “Buy” rating on the stock at the closing price of US $24.88 as of November 19th, 2025.
Disclaimer:
The information provided in this document and the resources available for download are intended for informational purposes only and should not be interpreted as financial advice. While the content is based on thorough research and is accurate to the best of our knowledge, it is not a substitute for professional financial guidance. We strongly recommend consulting with a financial advisor to discuss your specific situation and obtain tailored advice before making any financial decisions.
